<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MAXITROL- neomycin sulfate, polymyxin b sulfate and dexamethasone suspension </strong><br>Alcon Laboratories, Inc.<br></p></div>
<h1>
<span class="Bold">MAXITROL<span class="Sup">®</span></span><br><span class="Bold">(neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension)</span><br>Sterile
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First">MAXITROL® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is a multiple dose anti-infective steroid combination in sterile suspension form for topical application. The chemical structure for the active ingredient, dexamethasone, is:</p>
<div class="Figure"><img alt="
dexamethasone
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=277ff310-b7dc-43b6-8a16-885b58882bc0&amp;name=dexamethasone.jpg"></div>
<p>Established name: dexamethasone</p>
<p>Chemical name: pregna-1, 4-diene-3, 20-dione, 9-fluoro-11,17, 21-trihydroxy-16-methyl-, (11β, 16α)-.</p>
<p>The other active ingredients are neomycin sulfate and polymyxin B sulfate. The structural formula for neomycin sulfate is:</p>
<div class="Figure"><img alt="
neomycin
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=277ff310-b7dc-43b6-8a16-885b58882bc0&amp;name=neomycin.jpg"></div>
<p>The structural formula for polymyxin B sulfate is:</p>
<div class="Figure"><img alt="
polymyxin
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=277ff310-b7dc-43b6-8a16-885b58882bc0&amp;name=polymyxin.jpg"></div>
<p><span class="Bold">Each mL contains: Actives: </span>neomycin sulfate equivalent to neomycin 3.5 mg, polymyxin B sulfate 10,000 units, dexamethasone 0.1%. <span class="Bold">Inactives: </span>hypromellose 2910 0.5%, sodium chloride, polysorbate 20, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water, benzalkonium chloride 0.004% (preservative).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<p class="First">Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.</p>
<p>When a decision to administer both a corticosteroid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained. The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First">For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a risk of <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> exists.</p>
<p>Ocular corticosteroids are indicated in inflammatory conditions of the papebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. They are also indicated in chronic <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and corneal injury from chemical, radiation or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>; or penetration of foreign bodies.</p>
<p>The use of a combination drug with an anti-infective component is indicated where the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.</p>
<p>The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: <span class="Italics">Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter </span>species, <span class="Italics">Neisseria </span>species, and <span class="Italics">Pseudomonas aeruginosa</span>.</p>
<p>This product does not provide adequate coverage against: <span class="Italics">Serratia marcesens </span>and streptococci, including <span class="Italics">Streptococcus pneumoniae</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First">MAXITROL® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures. MAXITROL® is also contraindicated in individuals with known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients of this preparation and to other corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS
</h1>
<p class="First">Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with damage to the optic nerve, defects in visual acuity and fields of vision, and in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and <span class="product-label-link" type="condition" conceptid="4088088" conceptname="Scleral thinning">scleral thinning</span>. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.</p>
<p>Acute purulent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye may be masked or activity enhanced by the presence of corticosteroid medication.</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Intraocular pressure should be checked frequently. The use of steroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of bleb formation.</p>
<p>Use of ocular steroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.</p>
<p>MAXITROL® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye. Products containing neomycin sulfate may cause cutaneous sensitization.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-6.1"></a><p></p>
<h2>
General
</h2>
<p class="First">The initial prescription and renewal of the medication order beyond 20 mL of MAXITROL® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.</p>
<p>As <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications, fungal invasion should be suspected in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be monitored (see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>).  Prolonged use of topical anti-bacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6.2"></a><p></p>
<h2>
Information for Patients
</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician.</p>
<p>This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Keep bottle tightly closed when not in use. Keep out of reach of children.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-6.3"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate. Treatment of cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro </span>with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 μg/mL) tested. However, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-6.4"></a><p></p>
<h2>
Pregnancy
</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="splSectionPrecautionsPregnancyTerat"></a><a name="section-6.5"></a><p></p>
<h2>
Teratogenic Effects
</h2>
<p class="First"><span class="Bold">Pregnancy Category C.  </span>Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose.</p>
<p>In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc. There are no adequate or well-controlled studies in pregnant women. MAXITROL® Suspension should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-6.6"></a><p></p>
<h2>
Nursing Mothers
</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXITROL® Ophthalmic Suspension is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-6.7"></a><p></p>
<h2>
Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-6.8"></a><p></p>
<h2>
Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-7"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.</p>
<p>Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. The reactions due to the corticosteroid component are: elevation of intraocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>; <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation; and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing. Corticosteroid-containing preparations have also been reported to cause perforation of the globe. <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcers</span>, and <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> have occasionally been reported following use of steroids.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-8"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First">One to two drops in the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> subsides. In mild disease, drops may be used up to four to six times daily.</p>
<p>Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in <span class="Underline"><a href="#splSectionPrecautions">PRECAUTIONS</a></span> above.</p>
<p>FOR TOPICAL OPHTHALMIC USE ONLY.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-9"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First">MAXITROL® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is supplied as a sterile ophthalmic suspension in a white, low density polyethylene DROP-TAINER® dispenser with a pink, polypropylene cap.</p>
<p>5 mL in 8 mL bottle (<span class="Bold">NDC </span>0998-0630-06)</p>
<p><span class="Bold">STORAGE: </span>Store upright at 8° - 27°C (46° - 80° F).</p>
<p>Rx Only</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-10"></a><p></p>
<p class="First">Revised: April 2008</p>
<p>Printed in USA</p>
<p>© 2000, 2007, 2008 Alcon, Inc.</p>
<p>ALCON LABORATORIES, INC.</p>
<p>Fort Worth, Texas 76134 USA</p>
<p><span class="Bold">9003574-0408</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-11"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<p class="First"><span class="Bold">NDC</span> 0998-0630-06</p>
<p><span class="Bold">Alcon<span class="Sup">®</span></span></p>
<p><span class="Bold">Maxitrol<span class="Sup">®</span></span></p>
<p>(neomycin and</p>
<p>polymyxin B sulfates</p>
<p>and dexamethasone</p>
<p>ophthalmic</p>
<p>suspension)</p>
<p><span class="Bold">5 mL   Sterile</span></p>
<div class="Figure"><img alt="
carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=277ff310-b7dc-43b6-8a16-885b58882bc0&amp;name=carton.jpg"></div>
<div class="Figure"><img alt="
label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=277ff310-b7dc-43b6-8a16-885b58882bc0&amp;name=label.jpg"></div>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAXITROL 		
					</strong><br><span class="contentTableReg">neomycin sulfate, polymyxin b sulfate and dexamethasone suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0998-0630</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">3.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B SULFATE</td>
<td class="formItem">10000 [USP'U]  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXAMETHASONE</strong> (DEXAMETHASONE) </td>
<td class="formItem">DEXAMETHASONE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (4000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0998-0630-06</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050023</td>
<td class="formItem">11/15/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">008018525</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d114106c-3e46-4870-9d7b-2260ca28229f</div>
<div>Set id: 277ff310-b7dc-43b6-8a16-885b58882bc0</div>
<div>Version: 3</div>
<div>Effective Time: 20110816</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
